Last A$0.18 AUD
Change Today +0.005 / 2.94%
Volume 172.1K
ISN On Other Exchanges
As of 1:52 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

isonea ltd (ISN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/24/13 - A$0.88
52 Week Low
08/19/14 - A$0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ISONEA LTD (ISN)

Related News

No related news articles were found.

isonea ltd (ISN) Related Businessweek News

No Related Businessweek News Found

isonea ltd (ISN) Details

iSonea Limited is engaged in the research, development, and commercialization of a suite of medical devices; and production and sale of mobile health applications primarily in Australia, Israel, and the United States. The company offers PulmoTrack that is used in a doctor’s office to measure wheeze rate; Wheezometer for monitoring asthma; and WHolter, an ambulatory 24-hour recorder, which provides information about wheezing and coughing for patients with nocturnal asthma, COPD, occupational asthma, chronic cough, or allergies. It also provides AsthmaSense Cloud software, which keeps the track of symptoms, triggers, lung function measurements, and medication usage, as well as acts as a Web-based portal to access and review the information for various users; and AirSonea that provides information about asthma symptoms. The company was formerly known as KarmelSonix Ltd and changed its name to iSonea Limited in August 2011. iSonea Limited is based in Armadale, Australia.

isonea ltd (ISN) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: A$125.7K
Compensation as of Fiscal Year 2013.

isonea ltd (ISN) Key Developments

iSonea Appoints David Ashmore as New Director

iSonea Limited announced the appointment of new Non-Executive Director Mr. David Ashmore. Mr. Ashmore will also assume the role of Chairman of iSonea's Audit, Risk and Compliance Committee given his significant experience in Finance, Audit, Risk, and Governance in the private and public sectors.

iSonea Limited(ASX:ISN) added to S&P/ASX All Ordinaries Index

iSonea Limited(ASX:ISN) added to S&P/ASX All Ordinaries Index

Isonea Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2013

iSonea Limited reported consolidated earnings results for the half year ended December 31, 2013. For the period, the company reported total revenue of AUD 179,632 against AUD 36,963 a year ago. Loss before income tax expense was AUD 7,127,898 against AUD 2,897,122 a year ago. Loss attributable to owners of the parent entity was AUD 7,127,898 against AUD 2,897,122 a year ago. Diluted loss per share was 2.74 cents against 1.87 cents a year ago. The loss reflected negligible revenue, high expenses across a range of categories especially marketing, consulting and promotional costs, and the expensing of research and development. Net cash flows used in operating activities was AUD 5,002,113 against AUD 2,263,821 a year ago. Payment for purchases of plant and equipment was AUD 61,379 against AUD 789 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISN:AU A$0.18 AUD +0.005

ISN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ISN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ISN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,086.5x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,692.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISONEA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at